WO2004060262A3 - Modulators of notch signalling for use in immunotherpapy - Google Patents
Modulators of notch signalling for use in immunotherpapy Download PDFInfo
- Publication number
- WO2004060262A3 WO2004060262A3 PCT/GB2004/000046 GB2004000046W WO2004060262A3 WO 2004060262 A3 WO2004060262 A3 WO 2004060262A3 GB 2004000046 W GB2004000046 W GB 2004000046W WO 2004060262 A3 WO2004060262 A3 WO 2004060262A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- modulators
- notch signalling
- immunotherpapy
- antigen
- antigenic determinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
A product comprises i) a pharmaceutically acceptable support matrix suitable for in vivo administration bearing a multiplicity of modulators of Notch signalling; and ii) an antigen or antigenic determinant, or a polynucleotide coding for an antigen or antigenic determinant; as a combined preparation for simultaneous, contemporaneous, separate or sequential use for modulation of the immune system.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006500232A JP2006517533A (en) | 2003-01-23 | 2004-01-23 | Treatment of autoimmune diseases using activators of the Notch signaling pathway |
PCT/GB2004/000263 WO2004064863A1 (en) | 2003-01-23 | 2004-01-23 | Treatment of autoimmune diseases using an activator for the notch signaling pathway |
EP04722319A EP1646400B1 (en) | 2003-03-21 | 2004-03-22 | Treatment of allergic diseases using a modulator of the notch signaling pathway |
AT04722319T ATE474593T1 (en) | 2003-03-21 | 2004-03-22 | TREATMENT OF ALLERGIC DISEASES USING A MODULATOR OF THE NOTCH SIGNALING PATHWAY |
PCT/GB2004/001252 WO2004082710A1 (en) | 2003-03-21 | 2004-03-22 | Treatment of allergic diseases using a modulator of the notch signaling pathway |
US11/188,417 US20060204508A1 (en) | 2003-01-23 | 2005-07-25 | Treatment of autoimmune diseases using an activator for the notch signalling pathway |
US11/231,494 US20060205823A1 (en) | 2003-03-21 | 2005-09-21 | Treatment of allergic diseases using a modulator of the Notch signaling pathway |
US12/766,738 US20100303867A1 (en) | 2003-03-21 | 2010-04-23 | a composition comprising a notch ligand and an allergenb or allergen bystander antigen |
Applications Claiming Priority (36)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0300234A GB0300234D0 (en) | 2003-01-07 | 2003-01-07 | Medical treatment |
GB0300234.2 | 2003-01-07 | ||
GB0301529A GB0301529D0 (en) | 2003-01-23 | 2003-01-23 | Medical treatment |
GB0301510A GB0301510D0 (en) | 2003-01-23 | 2003-01-23 | Medical treatment |
GB0301513.8 | 2003-01-23 | ||
GB0301518A GB0301518D0 (en) | 2003-01-23 | 2003-01-23 | Medical treatment |
GB0301515.3 | 2003-01-23 | ||
GB0301515A GB0301515D0 (en) | 2003-01-23 | 2003-01-23 | Medical treatment |
GB0301519A GB0301519D0 (en) | 2003-01-23 | 2003-01-23 | Medical treatment |
GB0301529.4 | 2003-01-23 | ||
GB0301510.4 | 2003-01-23 | ||
GB0301527.8 | 2003-01-23 | ||
GB0301526.0 | 2003-01-23 | ||
GB0301521A GB0301521D0 (en) | 2003-01-23 | 2003-01-23 | Medical treatment |
GB0301512.0 | 2003-01-23 | ||
GB0301527A GB0301527D0 (en) | 2003-01-23 | 2003-01-23 | Medical treatment |
GB0301518.7 | 2003-01-23 | ||
GB0301521.1 | 2003-01-23 | ||
GB0301519.5 | 2003-01-23 | ||
GB0301512A GB0301512D0 (en) | 2003-01-23 | 2003-01-23 | Medical treatment |
GB0301513A GB0301513D0 (en) | 2003-01-23 | 2003-01-23 | Medical treatment |
GB0301522.9 | 2003-01-23 | ||
GB0301524.5 | 2003-01-23 | ||
GB0301522A GB0301522D0 (en) | 2003-01-23 | 2003-01-23 | Medical treatment |
GB0301526A GB0301526D0 (en) | 2003-01-23 | 2003-01-23 | Medical treatment |
GB0301524A GB0301524D0 (en) | 2003-01-23 | 2003-01-23 | Medical treatment |
GB0306621A GB0306621D0 (en) | 2003-03-22 | 2003-03-22 | Medical treatment |
GB0306621.4 | 2003-03-22 | ||
PCT/GB2003/001525 WO2003087159A2 (en) | 2002-04-05 | 2003-04-04 | Modulators of the notch signalling pathway and uses thereof in medical treatment |
GBPCT/GB03/001525 | 2003-04-04 | ||
GB0312062.3 | 2003-05-24 | ||
GB0312062A GB0312062D0 (en) | 2003-05-24 | 2003-05-24 | Medical treatment |
GBPCT/GB03/003285 | 2003-08-01 | ||
PCT/GB2003/003285 WO2004013179A1 (en) | 2002-08-03 | 2003-08-01 | Conjugate of notch signalling pathway modulators and their use in medical treatment |
GB0323130.5 | 2003-10-03 | ||
GB0323130A GB0323130D0 (en) | 2003-10-03 | 2003-10-03 | Medical treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004060262A2 WO2004060262A2 (en) | 2004-07-22 |
WO2004060262A3 true WO2004060262A3 (en) | 2004-12-09 |
Family
ID=56290518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2004/000046 WO2004060262A2 (en) | 2003-01-07 | 2004-01-07 | Modulators of notch signalling for use in immunotherpapy |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2004060262A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8835387B2 (en) | 2012-02-16 | 2014-09-16 | Atyr Pharma, Inc. | Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases |
US8986681B2 (en) | 2010-04-27 | 2015-03-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases |
US9127268B2 (en) | 2009-12-11 | 2015-09-08 | Atyr Pharma, Inc. | Aminoacyl tRNA synthetases for modulating inflammation |
US9422539B2 (en) | 2010-07-12 | 2016-08-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases |
US9587235B2 (en) | 2013-03-15 | 2017-03-07 | Atyr Pharma, Inc. | Histidyl-tRNA synthetase-Fc conjugates |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104830812B (en) | 2009-03-16 | 2017-09-05 | 盘古生物制药有限公司 | Composition and method comprising the Histidyl-tRNA-synthetase splicing variants with non-classical bioactivity |
US10782302B2 (en) * | 2012-05-04 | 2020-09-22 | Wayne State University | Detectors of serum biomarkers for predicting ovarian cancer recurrence |
US20160361240A1 (en) * | 2015-06-11 | 2016-12-15 | The Procter & Gamble Company | Apparatus and methods for modifying keratinous surfaces |
EP3612215A4 (en) | 2017-04-20 | 2021-05-26 | aTyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998020142A1 (en) * | 1996-11-07 | 1998-05-14 | Lorantis Limited | Notch |
WO2003041735A2 (en) * | 2001-11-14 | 2003-05-22 | Lorantis Limited | Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system |
WO2003087159A2 (en) * | 2002-04-05 | 2003-10-23 | Lorantis Limited | Modulators of the notch signalling pathway and uses thereof in medical treatment |
-
2004
- 2004-01-07 WO PCT/GB2004/000046 patent/WO2004060262A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998020142A1 (en) * | 1996-11-07 | 1998-05-14 | Lorantis Limited | Notch |
WO2003041735A2 (en) * | 2001-11-14 | 2003-05-22 | Lorantis Limited | Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system |
WO2003087159A2 (en) * | 2002-04-05 | 2003-10-23 | Lorantis Limited | Modulators of the notch signalling pathway and uses thereof in medical treatment |
Non-Patent Citations (5)
Title |
---|
HICKS C ET AL: "A SECRETED DELTA1-FC FUSION PROTEIN FUNCTIONS BOTH AS AN ACTIVATOR AND INHIBITOR OF NOTCH1 SIGNALING", JOURNAL OF NEUROSCIENCE RESEARCH, WILEY-LISS, US, vol. 68, no. 6, 15 June 2002 (2002-06-15), pages 655 - 667, XP009013890, ISSN: 0360-4012 * |
HOYNE G F ET AL: "SERRATE-1-INDUCED NOTCH SIGNALLING REGULATES THE DECISION BETWEEN IMMUNITY AND TOLERANCE MADE BY PERIPHERAL CD4+ T CELLS", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 12, no. 2, 2000, pages 177 - 185, XP000929552, ISSN: 0953-8178 * |
JANG M-S ET AL: "NOTCH SIGNALING AS A TARGET IN MULTIMODALITY CANCER THERAPY", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON,, GB, vol. 2, no. 1, February 2000 (2000-02-01), pages 55 - 65, XP009013844, ISSN: 1464-8431 * |
WONG K K ET AL: "Notch ligation by Delta1 inhibits peripheral immune responses to transplantation antigens by a CD8+ cell-dependent mechanism", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 112, no. 11, December 2003 (2003-12-01), pages 1741 - 1750, XP002268827, ISSN: 0021-9738 * |
ZLOBIN A ET AL: "TOWARD THE RATIONAL DESIGN OF CELL FATE MODIFIERS: NOTCH SIGNALING AS A TARGET FOR NOVEL BIOPHARMACEUTICALS", CURRENT PHARMACEUTICAL BIOTECHNOLOGY, BENTHAM SCIENCE PUBLISHERS, BOCA RATON,FL, US, vol. 1, no. 1, July 2000 (2000-07-01), pages 83 - 106, XP008004456, ISSN: 1389-2010 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9127268B2 (en) | 2009-12-11 | 2015-09-08 | Atyr Pharma, Inc. | Aminoacyl tRNA synthetases for modulating inflammation |
US9328340B2 (en) | 2009-12-11 | 2016-05-03 | Atyr Pharma, Inc. | Amino acyl tRNA synthetases for modulating inflammation |
US9540628B2 (en) | 2009-12-11 | 2017-01-10 | Atyr Pharma, Inc. | Aminoacyl tRNA synthetases for modulating inflammation |
US8986681B2 (en) | 2010-04-27 | 2015-03-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases |
US9580706B2 (en) | 2010-04-27 | 2017-02-28 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases |
US9422539B2 (en) | 2010-07-12 | 2016-08-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases |
US8835387B2 (en) | 2012-02-16 | 2014-09-16 | Atyr Pharma, Inc. | Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases |
US9273302B2 (en) | 2012-02-16 | 2016-03-01 | Atyr Pharma, Inc. | Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases |
US9587235B2 (en) | 2013-03-15 | 2017-03-07 | Atyr Pharma, Inc. | Histidyl-tRNA synthetase-Fc conjugates |
Also Published As
Publication number | Publication date |
---|---|
WO2004060262A2 (en) | 2004-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR016310A1 (en) | FROZEN COMPOSITE DESSERT AND THE METHOD TO PREPARE | |
NO20014035L (en) | Oral drug administration system | |
GB9818627D0 (en) | Improvements in dva vaccination | |
WO2000021572A3 (en) | Hydrogels and water soluble polymeric carriers for drug delivery | |
EP2481422A3 (en) | Multiplex vaccines | |
EP2311488A3 (en) | Vaccine composition | |
PL351893A1 (en) | Vaccines | |
AP9801392A0 (en) | Concentrated antibody preparation. | |
AU2003280711A1 (en) | Titania-metal composite and method for preparation thereof, and film forming method using dispersion comprising the composite | |
WO2002060422A3 (en) | Treatment of diabetes mellitus using vardenafil | |
UY26297A1 (en) | VACCINE | |
WO2004060262A3 (en) | Modulators of notch signalling for use in immunotherpapy | |
HK1045113A1 (en) | Oral administration form for administering a fixed tramadol and diclofenac combination | |
WO2006031787A3 (en) | Low-obscuration image transmitting particulate ocular therapeutic formulations | |
AU2003297199A1 (en) | Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof | |
ZA200007548B (en) | Matrix table enabling the prolonged release of trimetazidine after administration by the oral route. | |
WO2002096367A3 (en) | Targeted multivalent macromolecules | |
AU777185C (en) | Pharmaceutical form of administration for peptides, methods for its production and use | |
WO2000067788A3 (en) | Use of soluble costimulatory molecules to enhance immune responses | |
WO1997005899A3 (en) | Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same | |
ZA200203294B (en) | N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them. | |
WO2003054025A3 (en) | Amphoteric polysaccharide, composition and use | |
MXPA03006249A (en) | 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof. | |
ZA200110244B (en) | Novel xanthone compounds, their preparation and use as medicament. | |
DE60003662D1 (en) | PYRIDOTHIENODIAZEPINE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |